Skip to main content
Erschienen in: Current Oncology Reports 2/2018

01.02.2018 | Head and Neck Cancers (EY Hanna, Section Editor)

Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma

verfasst von: Moran Amit, Shorook Na’ara, Ehab Y. Hanna

Erschienen in: Current Oncology Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Sinonasal mucosal melanoma (SNMM) is a rare oncological entity that comprises most head and neck mucosal melanomas. SNMM has distinctive genetic background, different from cutaneous melanoma. Survival outcomes among SNMM patients are poor; while there is no clear consensus on the optimal management of SNMM, the primary treatment modality is generally considered to be wide surgical excision, and radiation therapy (RT) is often used in the postoperative adjuvant setting to improve locoregional control. Systemic therapies have demonstrated little or no survival benefit, and most SNMM patients die of distant metastatic disease. Owing to the rarity of the disease, the literature describing treatment approaches for SNMM is lacking and largely limited to isolated case reports and retrospective series. Here, we describe contemporary diagnostic and therapeutic approaches to SNMM based on the most recent molecular and outcome data.
Literatur
4.
6.
Zurück zum Zitat Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, et al. Localized sinonasal mucosal melanoma: outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & Neck. Sep 2016;38(9):1310–7. https://doi.org/10.1002/hed.24435.CrossRef Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, et al. Localized sinonasal mucosal melanoma: outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & Neck. Sep 2016;38(9):1310–7. https://​doi.​org/​10.​1002/​hed.​24435.CrossRef
13.
Zurück zum Zitat Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathol : Off J United States and Can Acad Pathol, Inc. 2009;22(11):1446–56. https://doi.org/10.1038/modpathol.2009.116.CrossRef Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathol : Off J United States and Can Acad Pathol, Inc. 2009;22(11):1446–56. https://​doi.​org/​10.​1038/​modpathol.​2009.​116.CrossRef
21.
Zurück zum Zitat Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer J Int Du Cancer. 2007;121(2):257–64. https://doi.org/10.1002/ijc.22681.CrossRef Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer J Int Du Cancer. 2007;121(2):257–64. https://​doi.​org/​10.​1002/​ijc.​22681.CrossRef
23.
Zurück zum Zitat Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res : Off J Am Assoc Cancer Res. 17(7):1684–1691. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res : Off J Am Assoc Cancer Res. 17(7):1684–1691.
51.
Zurück zum Zitat Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(26):3182–90. https://doi.org/10.1200/JCO.2012.47.7836.CrossRef Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(26):3182–90. https://​doi.​org/​10.​1200/​JCO.​2012.​47.​7836.CrossRef
52.
Zurück zum Zitat •• Dummer R. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016;34(suppl):abstr 9500. The first paper to show efficacy of NRAS targeting in mucosal melanoma. •• Dummer R. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016;34(suppl):abstr 9500. The first paper to show efficacy of NRAS targeting in mucosal melanoma.
55.
Zurück zum Zitat • D’Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol : Off J Am Soc Clin Oncol. 2017;35(2):226–35. Recent paper discussing the results of immunotherapy in mucosal melanoma. https://doi.org/10.1200/JCO.2016.67.9258.CrossRef • D’Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol : Off J Am Soc Clin Oncol. 2017;35(2):226–35. Recent paper discussing the results of immunotherapy in mucosal melanoma. https://​doi.​org/​10.​1200/​JCO.​2016.​67.​9258.CrossRef
56.
Zurück zum Zitat Butler M. The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors. Eur Cancer Congr. 2017;Abstract 1142. Butler M. The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors. Eur Cancer Congr. 2017;Abstract 1142.
58.
Zurück zum Zitat Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(35):5748–54. https://doi.org/10.1200/JCO.2008.17.5448.CrossRef Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(35):5748–54. https://​doi.​org/​10.​1200/​JCO.​2008.​17.​5448.CrossRef
60.
62.
Zurück zum Zitat Saigal K, Weed DT, Reis IM, Markoe AM, Wolfson AH, Nguyen-Sperry J. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol. 2012;2012:785131.PubMedPubMedCentral Saigal K, Weed DT, Reis IM, Markoe AM, Wolfson AH, Nguyen-Sperry J. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol. 2012;2012:785131.PubMedPubMedCentral
63.
Zurück zum Zitat Douglas CM, Malik T, Swindell R, Lorrigan P, Slevin NJ, Homer JJ. Mucosal melanoma of the head and neck: radiotherapy or surgery? J Otolaryngol - Head & Neck Surgery = Le J d'Oto-Rhino-laryngologie et de chirurgie cervico-faciale. 2010;39(4):385–92. Douglas CM, Malik T, Swindell R, Lorrigan P, Slevin NJ, Homer JJ. Mucosal melanoma of the head and neck: radiotherapy or surgery? J Otolaryngol - Head & Neck Surgery = Le J d'Oto-Rhino-laryngologie et de chirurgie cervico-faciale. 2010;39(4):385–92.
68.
Zurück zum Zitat Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8(7):1131–4.CrossRefPubMed Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8(7):1131–4.CrossRefPubMed
74.
Zurück zum Zitat • Greenwalt RD JC, Bryant CM, Morris CG, Mendenhall WM. Proton therapy for sinonasal mucosal melanoma. Int J Radiat Oncol*Biol*Phys. 2015;93(Issue 3, Supplement):E293. Recent paper showing that proton therapy can be utilized to escalate the dose in sinonasal mucosal melanoma while sparing uninvolved optic structures and help preserve vision. https://doi.org/10.1016/j.ijrobp.2015.07.1285.CrossRef • Greenwalt RD JC, Bryant CM, Morris CG, Mendenhall WM. Proton therapy for sinonasal mucosal melanoma. Int J Radiat Oncol*Biol*Phys. 2015;93(Issue 3, Supplement):E293. Recent paper showing that proton therapy can be utilized to escalate the dose in sinonasal mucosal melanoma while sparing uninvolved optic structures and help preserve vision. https://​doi.​org/​10.​1016/​j.​ijrobp.​2015.​07.​1285.CrossRef
Metadaten
Titel
Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma
verfasst von
Moran Amit
Shorook Na’ara
Ehab Y. Hanna
Publikationsdatum
01.02.2018
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 2/2018
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-018-0660-7

Weitere Artikel der Ausgabe 2/2018

Current Oncology Reports 2/2018 Zur Ausgabe

Neuro-oncology (S Nagpal, Section Editor)

Updates on Primary Central Nervous System Lymphoma

Geriatric Oncology (AR MacKenzie, Section Editor)

Melanoma Immunotherapy in the Elderly

Head and Neck Cancers (EY Hanna, Section Editor)

Immunotherapy for Head and Neck Squamous Cell Carcinoma

Gastrointestinal Cancers (J Meyer, Section Editor)

Updates on Gallbladder Cancer Management

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.